D-0649-2016 Class II Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-0649-2016 was initiated by Pfizer Inc. on Jan 11, 2016 and is designated Class II. Reason for recall: FAILED TABLET/CAPSULE SPECIFICATIONS: Firm is recalling specific lots of pregabalin capsules due to the potential presence of deformed or damaged capsules. The recall status is terminated (terminated Apr 24, 2017). Affected quantity: 116,400 bottles.

Recall details

Product Type
Drugs
Report Date
Feb 10, 2016
Initiation Date
Jan 11, 2016
Termination Date
Apr 24, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
116,400 bottles

Product description

Lyrica (pregabalin) capsules, 75 mg, 90-count bottle, Rx only, Distributed by: Parke-Davis, Division of Pfizer Inc., NY, NY 10017, NDC 0071-1014-68

Reason for recall

FAILED TABLET/CAPSULE SPECIFICATIONS: Firm is recalling specific lots of pregabalin capsules due to the potential presence of deformed or damaged capsules.

Distribution pattern

Nationwide and Puerto Rico

Code information

Lot #: M07862, Exp 05/2018; M07865, Exp 06/2018

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0649-2016
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-0649-2016. Report a data issue: hello@regdatalab.com.